Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(25)
•••
Comment by smush74on Jun 08, 2015 12:53pm
62 Views
Post# 23807521

RE:RE:RE:RE:RE:RE:RE:Received from TD Waterhouse

RE:RE:RE:RE:RE:RE:RE:Received from TD WaterhouseJust go to their website, (could be out of date) besides 2-3-4 doesn't change the fundamentals of the company.

Firm Analyst Phone
Cormark Securities Inc. David Dean, MSc, MBA 416-943-6397
Euro Pacific Canada Douglas Loe, Ph.D MBA 416 775-1004
Laurentian Bank Securities Joseph Walewicz, MBA, CFA 514 350-2914
Zacks Investment Research Jason Napodano, CFA 312-265-9421

link to cipher

Of the three analysts surveyed by Reuters Estimates that cover Cipher Pharmaceuticals Inc, the consensus rating is a buy. The rating changed on June 01, 2015 when it was upgraded from a sell.

Do you homewok and buy or sell based on your comfort level not analysts.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities